|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - KRW | -.--% |
|
-.--% | - |
| 05-14 | SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 03-23 | SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 56.46B 37.97M 33.18M 30.62M 28.22M 53.2M 3.66B 54.38M 366M 144M 1.79B 143M 139M 6.17B | P/E 2024 |
-16x | P/E 2025 | -19.2x |
|---|---|---|---|---|---|
| Enterprise Value | 79B 53.13M 46.43M 42.84M 39.49M 74.43M 5.12B 76.08M 512M 201M 2.51B 200M 195M 8.63B | EV / Sales 2024 |
13.3x | EV / Sales 2025 | 4.57x |
| Free-Float |
45.72% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyung-Yul Lee
CEO | Chief Executive Officer | - | 2022-12-27 |
Se-Yeon Baek
CEO | Chief Executive Officer | 59 | 2024-09-29 |
Dae-Young Kim
AUD | Comptroller/Controller/Auditor | 63 | 2022-12-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Se-Yeon Baek
BRD | Director/Board Member | 59 | 2024-09-29 |
Kyung-Yul Lee
BRD | Director/Board Member | - | 2022-12-27 |
Jeong-Gyun Choi
BRD | Director/Board Member | 59 | 2024-09-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 37.97M | |
| -0.33% | +1.83% | +24.73% | -5.89% | 68.85B | |
| +0.67% | +0.93% | +36.86% | +194.41% | 52.13B | |
| +0.94% | +39.60% | +39.60% | +39.60% | 43.46B | |
| -0.80% | +0.79% | -52.10% | -53.90% | 41.24B | |
| -1.40% | +3.43% | +64.81% | -25.61% | 30.41B | |
| -2.11% | -9.45% | +97.76% | -50.61% | 24.53B | |
| +0.51% | +0.46% | +72.78% | +86.41% | 23.42B | |
| -5.57% | -0.84% | -0.11% | +189.27% | 19.75B | |
| -0.86% | -1.99% | +70.03% | +124.61% | 16.57B | |
| Average | -0.90% | -0.58% | +39.37% | +55.37% | 35.6B | |
| Weighted average by Cap. | -0.59% | +0.08% | +32.55% | +46.93% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.74B 3.19M 2.78M 2.57M 2.37M 4.46M 307M 4.56M 30.71M 12.08M 150M 11.96M 11.7M 517M | 22.01B 14.8M 12.94M 11.94M 11M 20.74M 1.43B 21.2M 143M 56.12M 698M 55.59M 54.37M 2.4B |
| Net income | -3.73B -2.51M -2.19M -2.02M -1.86M -3.51M -242M -3.59M -24.18M -9.51M -118M -9.42M -9.21M -407M | -3.93B -2.65M -2.31M -2.13M -1.97M -3.71M -255M -3.79M -25.5M -10.03M -125M -9.94M -9.72M -430M |
| Net Debt | 3.15B 2.12M 1.85M 1.71M 1.57M 2.96M 204M 3.03M 20.39M 8.02M 99.76M 7.94M 7.77M 343M | 22.53B 15.15M 13.24M 12.22M 11.26M 21.23M 1.46B 21.7M 146M 57.45M 715M 56.91M 55.66M 2.46B |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
